Serial Number | 97389517 |
Word Mark | EMULATE THERAPEUTICS |
Filing Date | Friday, April 29, 2022 |
Status | 604 - ABANDONED - AFTER INTER-PARTES DECISION |
Status Date | Wednesday, February 14, 2024 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
Published for Opposition Date | Tuesday, July 18, 2023 |
Goods and Services | Medical apparatus for use in treating cancer, pain, inflammation, and solid cancer tumors such as mycosis fungoides, plasma cell tumors, fibrosarcomas, neurofibrosarcomas, schwannomas, malignant melanomas, hermangiopericytomas, hepatic adenocarcinomas, mast cell tumors, mammary adenocarcinomas, osteosarcomas, chondrosarcomas, apocrine glandadenocarcinomas, undifferentiated carcinomas, and transitional cell carcinomas tumors, and mental health conditions, namely, PTSD, depression, anxiety and addiction; Medical device for treating cancer |
Disclaimer with Predetermined Text | "THERAPEUTICS" |
Goods and Services | Product development in the field of medical device technology; Research and development in the field of medical device technology for use in treating cancer, pain, inflammation, tumors, and a wide range of ailments and disease; Research and development of technology in the field of disease treatment |
International Class | 010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials. |
US Class Codes | 026, 039, 044 |
Class Status Code | 8 - Abandoned |
Class Status Date | Wednesday, February 14, 2024 |
Primary Code | 010 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
US Class Codes | 100, 101 |
Class Status Code | 8 - Abandoned |
Class Status Date | Wednesday, February 14, 2024 |
Primary Code | 042 |
First Use Anywhere Date | Friday, November 30, 2018 |
First Use In Commerce Date | Friday, November 30, 2018 |
Party Name | EMulate Therapeutics, Inc. |
Party Type | 20 - Owner at Publication |
Legal Entity Type | 03 - Corporation |
Address | Seattle, WA 98109 |
Party Name | EMulate Therapeutics, Inc. |
Party Type | 10 - Original Applicant |
Legal Entity Type | 03 - Corporation |
Address | Seattle, WA 98109 |
Event Date | Event Description |
Thursday, February 15, 2024 | ABANDONMENT NOTICE E-MAILED - INTER PARTES DECISION |
Wednesday, February 14, 2024 | OPPOSITION TERMINATED NO. 999999 |
Wednesday, February 14, 2024 | OPPOSITION SUSTAINED NO. 999999 |
Wednesday, February 14, 2024 | ABANDONMENT - AFTER INTER PARTES DECISION |
Wednesday, November 15, 2023 | OPPOSITION INSTITUTED NO. 999999 |
Friday, August 11, 2023 | EXTENSION OF TIME TO OPPOSE RECEIVED |
Tuesday, July 18, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Tuesday, July 18, 2023 | PUBLISHED FOR OPPOSITION |
Wednesday, June 28, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Wednesday, June 14, 2023 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
Wednesday, June 7, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
Wednesday, June 7, 2023 | EXAMINER'S AMENDMENT ENTERED |
Wednesday, June 7, 2023 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
Wednesday, June 7, 2023 | EXAMINERS AMENDMENT E-MAILED |
Wednesday, June 7, 2023 | EXAMINERS AMENDMENT -WRITTEN |
Tuesday, June 6, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
Tuesday, June 6, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Tuesday, June 6, 2023 | ASSIGNED TO LIE |
Friday, February 17, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Friday, February 17, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Friday, February 17, 2023 | NON-FINAL ACTION E-MAILED |
Friday, February 17, 2023 | NON-FINAL ACTION WRITTEN |
Thursday, February 16, 2023 | ASSIGNED TO EXAMINER |
Wednesday, May 4, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Tuesday, May 3, 2022 | NEW APPLICATION ENTERED |